Kainos Medicine카이노스메드
284620 · KOSDAQ · ₩284620 · 카이노스메드
- Market cap
- ₩36B
- Enterprise value
- ₩35B
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- 501.8%
- Net margin
- −450.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range0.0% from the high
₩1,087Today: ₩1,087 – ₩1,087₩1,087
Returns
- 1W0.0%
- 1M0.0%
- 3M0.0%
- 6M0.0%
- YTD0.0%
- 1Y0.0%
- Volume today
- —
- Traded today
- —
- Listed shares
- 33,086,953
- EPS (12 months)
- −₩191
- Earnings yield −17.6%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumFlat0% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Kainos Medicine stock overview
Kainos Medicine (카이노스메드, KRX: 284620) is listed on KOSDAQ, in the Biotech & Pharma sector. The company researches and develops biotechnology-based drugs for diseases with no adequate treatments, including neurological, antiviral and cancer indications. Its shares closed at ₩1,087 on Oct 26, 2026, unchanged on the day, giving it a market value of ₩36B.
Key facts
- Market cap
- ₩36B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 26, 2026
- Main business
- The company researches and develops biotechnology-based drugs for diseases with no adequate treatments, including neurological, antiviral and cancer indications.
Quick answers about Kainos Medicine
- What does Kainos Medicine do?
- The company researches and develops biotechnology-based drugs for diseases with no adequate treatments, including neurological, antiviral and cancer indications. Its business model is to license out drug candidates to pharmaceutical partners at suitable development stages, and its revenue comes from licensing fees, milestones and royalties. S.
- What is the market cap of Kainos Medicine?
- The market capitalisation of Kainos Medicine was ₩36B at the close on Oct 26, 2026.
- Who are the largest shareholders of Kainos Medicine?
- According to the latest official filings, the largest reported holders are Lee Ki-seop (12.94%, as of May 21, 2025); Naun Holdings (6.42%, as of Mar 28, 2025); Kim Han Jun (5.58%, as of Apr 3, 2025).
- When is the next earnings report from Kainos Medicine?
- Korean companies rarely announce results dates in advance. Based on when Kainos Medicine filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company researches and develops biotechnology-based drugs for diseases with no adequate treatments, including neurological, antiviral and cancer indications. Its business model is to license out drug candidates to pharmaceutical partners at suitable development stages, and its revenue comes from licensing fees, milestones and royalties. Its lead Parkinson's candidate is in clinical trials in the United States through a U.S. subsidiary, and its HIV treatment has been licensed to a Chinese partner that has launched products in China.
Written by AI from the company's latest annual report.
- Korean name
- 카이노스메드
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 이기섭
- Founded
- Nov 2017
- Listed
- Jun 2018
- Listed shares
- 33,086,953
- Fiscal year ends
- Month 12
- Website
- www.kainosmedicine.com
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent filings
See all- Other Market Notice (Non-Implementation of Market Measures Following Addition of Grounds for Investment Caution Designation and Non-Implementation of Procedures Following Addition of Grounds for Substantive Review of Listing Eligibility)Aug 14, 2026
- Confirmation of Facts Such as Adverse Opinion on Semi-annual Review (Audit), Including Capital Impairment Ratio of 50% or More or Equity Under ₩1BAug 14, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Change of Head Office LocationJun 16, 2026
- Amended: Sales or supply contract terminatedMay 29, 2026
Titles in Korean until English translations are added.
Also known as: Kainos Medicine / 카이노스메드 / 284620 / KRX:284620
Source: KRX statistical information